Death associated protein kinase as a potential therapeutic target

Bibliography

• DEISS LP, FEINSTEIN E, BERISSI H, COHEN 0, KIMCHI A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the y interferon-induced cell death. Genes Dev. (1995) 9:15–30.
   PubMed Web of Science ®Google Scholar
• ••Describes the identification of DAPK.
   Google Scholar
• SHOEMAKER MO, LAU W, SHATTUCK RL et aL: Use of DNA sequence and mutant analyses and antisense oligodeoxynucleotides to examine the molecular basis of nonmuscle myosin light chain kinase autoinhibition, calmodulin recognition and activity. Cell Biol. (1990) 111:1107–1125.
   PubMed Web of Science ®Google Scholar
• •Describes the identification of MLCK functional domains.
   Google Scholar
• WATTERSON DM, COLLINGE M, LUKAS TJ et al.: Multiple gene products are produced from a novel protein kinase transcription region. FEBS Lett. (1995) 373:217–220.
   PubMedGoogle Scholar
• YAMAMOTO M, TAKAHASHI H, NAKAMURA T et al.: Developmental changes in distribution of death-associated protein kinase mRNAs. Neurosci. Res. (1999) 58:674–683.
   Google Scholar
• ••Paper that correlates changes in DAPKmRNA with cell death in animal models of forebrain ischaemia.
   Google Scholar
• MCCULLOUGH LD,BEAUCHAMP NB, WITYK R: Recent advances in the diagnosis and treatment of stroke. Surv. Ophthahnol (2001) 45:317–330.
   PubMedGoogle Scholar
• •A review of stroke treatments in use or in clinical trials.
   Google Scholar
• HATTON J: Pharmacological treatment of traumatic brain injury. CNS Drugs (2001) 15:553–581.
   PubMed Web of Science ®Google Scholar
• •A review of treatments for traumatic brain injury.
   Google Scholar
• RAVEH T, DROGUETT G,HORWITZ MS, DEPINHO RA, KIMCHI A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nature Cell Biol. (2001) 3:1–7.
   PubMed Web of Science ®Google Scholar
• •Reports links between DAPK and the p53 pathway.
   Google Scholar
• COHEN 0, INBAL B, KISSIL JL et al.:DAP-kinase participates in TNF-a- and Fas-induced apoptosis and its function requires the death domain. Cell Biol. (1999) 146:141–148.
   Google Scholar
• LARNER AJ: Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Expert Opin. Ther. Patents(2000) 10:1493–1518.
   Web of Science ®Google Scholar
• ••A review of apoptosis as a therapeutic targetin neurodegenerative disease.
   Google Scholar
• TANG X, KHURI FR, LEE JJ et al: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I nonsmall-cell lung cancer. J. Natl Cancer Inst. (2000) 92:1511–1516.
   PubMed Web of Science ®Google Scholar
• ZOCHBAUER-MULLER S, FONG KM, VIRMANI AK, GERADTS J,GAZDAR AF, MINNA JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. (2001) 61:249–255.
   PubMed Web of Science ®Google Scholar
• NAKATSUKA S-I, TAKAKUWA T, TOMITA Y, MIWA H, MATSUZUKA F, AOZASA K: Role of hypermethylation of DAP-kinase CpG island in the development of thyroid lymphoma. Lab. Invest. (2000) 80:1651–1655.
   PubMedGoogle Scholar
• KATZENELLENBOGEN RA,BAYLIN SB, HERMAN JG:Hypermethylation of the DAP-kinase CpG island is a common alteration in B cell malignancies. Blood (1999) 93:4347–4353.
   PubMed Web of Science ®Google Scholar
• KANG GH, SHIMY-H, JUNG H-Y, KIM WH, RO JY, RHYU M-G: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. (2001) 61:2847–2851.
   PubMedGoogle Scholar
• DONG SM, KIM H-S, RHA S-H, SIDRANSKY D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Cliri. Cancer Res. (2001) 7:1982–1986.
   PubMedGoogle Scholar
• WONG TS, CHANG HW,TANG KC et al.: High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin. Cancer Res. (2002) 8:433–437.
   Google Scholar
• DONG SM, PANG JC, POON WS et al:Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumours. J. Neuropath. Exp. Neurology (2001) 60:808–816.
   PubMed Web of Science ®Google Scholar
• SIMPSON DJ, CLAYTON RN, FARRELL WE: Preferential loss of death associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene (2002) 21:1217–1224.
   PubMed Web of Science ®Google Scholar
• KNUDSON AG: Two genetic hits (more or less) to cancer. Nat. Rev Cancer (2001) 1:157–162.
   PubMed Web of Science ®Google Scholar
• •Review of the two-hit hypothesis for the development of cancer.
   Google Scholar
• TERESHKO V, TEPLOVA M, BRUNZELLE J, WATTERSON DM, EGLI M: Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumour suppression. Nat. Struct. Biol. (2001) 8:899–907.
   PubMedGoogle Scholar
• ••Report of the crystal structure of theDAPK catalytic domain, the highest resolution structure for any kinase, which reveals new details of kinases and novel features of DAPK.
   Google Scholar
• VELENTZA AV, SCHUMACHER AM, WEISS C, EGLI M, WATTERSON DM:A protein kinase associated with apoptosis and tumour suppression: structure, activity and discovery of peptide substrates.' Biol. Chen]. (2001) 276:38956-38965.This paper reports the development of a quantitative activity assay for DAPK and the biochemical characterisation of DAPK from vertebrate brain.
   Google Scholar
• VELENTZA AV, SCHUMACHER AM, WATTERSON DM: Structure, activity, regulation and inhibitor discovery for a protein kinase associated with apoptosis and neuronal death. Pharinacol flier. (2002) In press.
   Google Scholar
• ••Description of a strategy used to discoverfirst generation small molecule inhibitors of DAPK catalytic activity.
   Google Scholar
• COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev Drug Discovery (2002) 1:309–315.
   PubMed Web of Science ®Google Scholar
• ••A current review of protein kinases astherapeutic targets.
   Google Scholar
• TRAXLER P, BOLD G,BUCHDUNGER E et al.: Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev (2001) 21:499–512.
   Google Scholar
• KUMAR CC, MADISON V: Drugs targeted against protein kinases. Expert Opin. Emerging Drugs (2001) 6:303–315.
   PubMedGoogle Scholar
• •A recent review of therapeutics that target protein kinases.
   Google Scholar
• SAWYERS CL: Rational therapeutic intervention in cancer: kinases as drug targets. Carr. Opin. Genet. Dev. (2002) 12:111–115.
   PubMed Web of Science ®Google Scholar
• •A recent review of therapeutics that target protein kinases.
   Google Scholar
• MIRZOEVA S, KOPPAL T,PETROVA TV, LUKAS TJ, WATTERSON DM, VAN ELDIK LJ: Screening in a cell-based assay for inhibitors of microglial nitric oxide production reveals calmodulin-regulated protein kinases as potential drug discovery targets. Brain Res. (1999) 844:126–134.
   PubMedGoogle Scholar
• MIRZOEVA S, SAWKAR A,ZASADZKI M et al.: Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound." Med. Chen]. (2002) 45:563–566.
   Google Scholar
• ••Reports a precedent for using a chemicalgenomics approach starting with phamacology focused libraries to discover new classes of selective kinase inhibitors that modulate cell activities related to disease end points in brain.
   Google Scholar
• DUMAS J: Growth factor receptor tyrosine kinase inhibitors: recent progress and clinical impact. Carr. Opin. Drug Disc. Dev. (2001) 4:378–389.
   PubMedGoogle Scholar
• ENGLISH JM, COBB MH: Pharmacological inhibitors of MAPK pathways. Trends Pharinacol ScL (2002) 23:40–45.
   PubMed Web of Science ®Google Scholar
• •Overview of current small molecule inhibitors of MAPK pathways.
   Google Scholar
• DRUKER BJ: 5TI571 (GleevecTh4) as a paradigm for cancer therapy. Trends Mol Med. (2002) 8:S14–S18.
   Google Scholar
• ••Review of the development of STI-571 forthe treatment of CML.
   Google Scholar
• STANGER BZ, LEDER P, LEE T-H, KIM E, SEED B: RIP: a novel protein containing a death domain that interacts with Fas/Apo-1 (CD95) in yeast and causes cell death. Cell (1995) 81:513–523.
   PubMed Web of Science ®Google Scholar
• COHEN 0, FEINSTEIN E, KIM CHI A: DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. (1997) 16:998–1008.
   PubMed Web of Science ®Google Scholar
• •The original report describing DAPK as a kinase.
   Google Scholar
• LOWE ED, NOBLE MEM,SKAMNAKI VT, OIKONOMAKOS NG, OWEN DJ, JOHNSON LN: The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. (1997) 16:6646–6658.
   PubMedGoogle Scholar
• LUKAS TJ, MIRZOEVA S,WATTERSON DM: Calmodulin-regulated protein kinases. In: Calmodulin and Signal Transduction. Van Eldik L, Watterson DM (Eds), Academic Press, New York, NY, USA (1998) 65–168.
   Google Scholar
• •A comprehensive review of calmodulin-regulated protein kinases with an emphasis on molecular themes that are still current.
   Google Scholar
• YAMAMOTO M, HIOKI T, ISHII T, NAKAJIMA-IIJIMA S, UCHINO S: DAP-kinase activity is critical for C2-ceramide-induced apoptosis in PC12 cells. Ear J. Biochein. (2002) 269:139–147.
   PubMedGoogle Scholar
• ••Description of the involvement of DAPKin ceramide-induced death of PC12 cells.
   Google Scholar
• JIN Y, BLUE EK, DIXON S, HOU L, WYSOLMERSKI RB, GALLAGHER PJ: Identification of a new form of death associated protein kinase that promotes cell survival. Biol. Chen]. (2001) 276:39667–39678.
   Google Scholar
• VELENTZA A, ZASADZKI M, HAIECH J, WAINWRIGHT M, VAN ELDIK L, WATTERSON DM: Discovery of a new class of bioavailable protein kinase inhibitors. 28th National Medicinal Chemistry Symposium. San Diego, CA, USA (2002) 111.
   Google Scholar
• INBAL B, SHANI G, COHEN 0, KISSEL JL, KIM CHI A: Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell. Biol. (2000) 20:1044–1054.
   PubMed Web of Science ®Google Scholar
• KAWAI T, MATSUMOTO M,TAKEDA K, SANJO H, AKIRA S: ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Ma Cell Biol. (1998) 18:1642–1651.
   Google Scholar
• KOGEL D, PLOTTNER 0, LANDSBERG G, CHRISTIAN S, SCHEIDTMANN KH: Cloning and characterization of Dlk, a novel serine/ threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Oncogene (1998) 17:2645–2654.
   PubMedGoogle Scholar
• JANG C-W, CHEN C-H, CHEN C-C, CHEN J-Y, SU Y-H, CHEN R-H: TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. (2002) 4:51–58.
   PubMedGoogle Scholar
• •A report that suggests DAPK is an effector in TGF-I3 pathways.
   Google Scholar
• PELLED D, RAVEHT, RIEBELING C et al.: Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons.j Biol. Chem. (2002) 277: 1957-1961.
   Google Scholar
• ••Description of DAPK as an effector ofceramide-induced cell death in cultured neurons.
   Google Scholar
• SCHUSTER N, KRIEGLSTEIN K: Mechanisms of TGF-P-mediated apoptosis. Cell Tissue Res. (2002) 307:1–14.
   PubMed Web of Science ®Google Scholar
• DE LUCA A, WELLER M, FONTANA A: TGF-beta-induced apoptosis of cerebellar granule neurons is prevented by depolarization. J. NeuroscL (1996) 16:4174–4185.
   PubMedGoogle Scholar
• NAKAO A, IMAMURA T, SOUCHELNYTSKYI S et al: TGF-I3 receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO (1997) 16:5353–5362.
   PubMed Web of Science ®Google Scholar
• GREEN DR, REED JC: Mitochondria andapoptosis. Science (1998) 281:1309–1312.
   PubMed Web of Science ®Google Scholar
• FREATHY C, BROWN DG,ROBERTS RA, CAIN K: Transforming growth factor-beta(1) induces apoptosis in rat Fa0 hepatoma cells via cytochrome c release and oligomerization of Apaf-1 to form an approximately 700-kd apoptosome caspase-processing complex. Hepatology (2000) 32:750–760.
   PubMed Web of Science ®Google Scholar
• KOMAROVA EA, GUDKOV AV: Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem. Pharm. (2001) 62:657–667.
   PubMed Web of Science ®Google Scholar
• •A review of p53 in neuronal death.
   Google Scholar
• SHERR CJ: Tumour surveillance via the ARF-p53 pathway. Genes Dev. (1998) 12:2984–2991.
   PubMed Web of Science ®Google Scholar
• SHERR CJ: The INK4a/ARF network intumour suppression. Nat. Rev Mol Bio. (2001) 2:731–737.
   PubMedGoogle Scholar
• MATHIAS S, PENA LA,KOLESNICK RN: Signal transduction of stress via ceramide. Biochem. 1 (1998) 335:465-480.
   Google Scholar
• RAVEH T, BERISSI H, EISENSTEIN M,SPIVAK T, KIMCHI A: A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its pro-apoptotic activity. Proc. Nati Acad. Sci. USA (2000) 97:1572–1577.
   PubMedGoogle Scholar
• READ SJ, PARSONS AA,HARRISON DC et al.: Stroke genomics: approaches to identify, validate and understand ischemic stroke gene expression. 1 Cervix Blood Flow Metal,. (2001) 21:755–778.
   Google Scholar
• NAKANE M, KUBOTA M, NAKAGOMI T et al.: Lethal forebrain ischaemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus. NeuroscL Lett. (2000) 296:89–92.
   PubMed Web of Science ®Google Scholar
• •This paper links ischaemia and ceramide production.
   Google Scholar
• SCHUMACHER AM, VELENTZA AV, WATTERSON DM, WAINWRIGHT MS: DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim. Biophys. Acta Submitted for publication.
   Google Scholar
• ESTELLER M, HERMAN JG: Cancer asan epigenetic disease: DNA methylation and chromatin alterations in human tumours. 1 Path. (2002) 196:1–7.
   PubMed Web of Science ®Google Scholar
• INBAL B, COHEN 0, POLAK-CHARCON S et al.: DAP kinase links the control of apoptosis to metastasis. Nature (1997) 390:180–184.
   Google Scholar
• •Description of an animal model that links restoration of DAPK expression to decreased metastatic potential.
   Google Scholar
• KISSIL JL, FEINSTEIN E,COHEN 0 et al.: DAP-kinase loss of expression in various carcinoma and B cell lymphoma cell lines: possible implications for role as tumour suppressor gene. Oncogene (1997) 15:403–407.
   Google Scholar
• SANTINI V, KANTARJIAN HM,ISSA J-P: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. (2001) 134:573–586.
   PubMed Web of Science ®Google Scholar
• BROWN R, STRATHDEE G: Epigenomics and epigenetic therapy of cancer. Trends Ma Med. (2002) 8:S43–S48.
   PubMed Web of Science ®Google Scholar
• •An overview of targeting epigenetic modifications in cancer.
   Google Scholar
• PLUMB JA, STRATHDEE G,SLUDDEN J, KAYE SB, BROWN R: Reversal of drug resistance in human tumour xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the 17MLHI gene promoter. Cancer Res. (2000) 60:6039–6044.
   PubMed Web of Science ®Google Scholar
• LIU P-Q, REBAR EJ, ZHANG L et al.: Regulation of an endogenous locus using a panel of designed zinc-finger proteins targeted to accessible chromatin regions. J. Biol. Chem. (2001) 276:11323–11334.
   PubMedGoogle Scholar
• •Report of an emerging technology that enables the upregulation of specific genes.
   Google Scholar
• NICHOLLS A, SHARP KA, HONIG B: Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins (1991) 11:281–296.
   PubMed Web of Science ®Google Scholar